![Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/public/attachments/8d03762d-8fab-4e85-9bf6-c5571441baf8/large/62035_anonymized_attachment_for_article_24422.png)
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology
![The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study | Scientific Reports The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-18889-z/MediaObjects/41598_2022_18889_Fig1_HTML.png)
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study | Scientific Reports
![Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs](https://www.spandidos-publications.com/article_images/ol/18/1/ol-18-01-0792-g02.jpg)
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs
![EGFR-mutated disease: early combinations and new approaches in exon 20 insertion-positive lung cancer - memoinOncology EGFR-mutated disease: early combinations and new approaches in exon 20 insertion-positive lung cancer - memoinOncology](https://memoinoncology.com/wp-content/uploads/2020/07/Graph-8-asco-2020-en-1024x596.png)
EGFR-mutated disease: early combinations and new approaches in exon 20 insertion-positive lung cancer - memoinOncology
![Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers](https://www.frontiersin.org/files/Articles/811601/fimmu-13-811601-HTML/image_m/fimmu-13-811601-g001.jpg)
Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers
![Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis](https://www.spandidos-publications.com/article_images/ol/20/3/ol-20-03-2266-g01.jpg)
Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
![The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-08449-w/MediaObjects/41598_2022_8449_Fig1_HTML.png)
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
![Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health – Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health –](https://www.thelancet.com/cms/attachment/7f8ca4e4-a1f7-470f-baca-e75c768839a8/gr1_lrg.jpg)
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health –
![Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-98275-3/MediaObjects/41598_2021_98275_Fig1_HTML.png)
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports
![Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09421-7/MediaObjects/12885_2022_9421_Fig1_HTML.png)
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
![Kaplan-Meier survival analysis of patients with NSCLC with or without... | Download Scientific Diagram Kaplan-Meier survival analysis of patients with NSCLC with or without... | Download Scientific Diagram](https://www.researchgate.net/publication/255791225/figure/fig1/AS:297817382899712@1448016605090/Kaplan-Meier-survival-analysis-of-patients-with-NSCLC-with-or-without-EGFR-mutations.png)
Kaplan-Meier survival analysis of patients with NSCLC with or without... | Download Scientific Diagram
![Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports](https://www.jtocrr.org/cms/asset/8f4c3979-0b4b-4c52-b990-627274e985fe/gr3.jpg)
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports
![Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies](https://www.frontiersin.org/files/Articles/635007/fonc-11-635007-HTML/image_m/fonc-11-635007-g001.jpg)
Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
![The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer | Scientific Reports The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsrep40374/MediaObjects/41598_2017_Article_BFsrep40374_Fig1_HTML.jpg)
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer | Scientific Reports
![First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-02561-z/MediaObjects/41598_2021_2561_Fig1_HTML.png)
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
![Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis | European Respiratory Society Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis | European Respiratory Society](https://erj.ersjournals.com/content/erj/41/2/417/F2.large.jpg)
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis | European Respiratory Society
![Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations](https://www.spandidos-publications.com/article_images/mco/8/3/mco-08-03-0421-g00.jpg)
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
![Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09421-7/MediaObjects/12885_2022_9421_Fig2_HTML.png)
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
![Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500218300059-gr2.jpg)
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect
![Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419345880-gr1.jpg)
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect
![Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology](https://onco-hema.healthbooktimes.org/article/36897-treatment-options-for-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations/attachment/93847.jpeg)
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
![Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer](https://www.spandidos-publications.com/article_images/mco/11/3/mco-11-03-0301-g00.jpg)